Podcast: Research Pulse, Episode 07.
Today we’re focusing on chronic myeloid leukaemia (CML) and research which is solving the problem of why some patients don’t respond to therapy.
- about the game-changing use of targeted drug therapy for CML
- that about 20% of patients with CML are resistant to targeted drug therapy
- about using next-generation sequencing to find the genetic mutations associated with drug resistance
Listen and subscribe
To listen to upcoming episodes, find us and subscribe wherever you get your podcasts.
Get in touch
We would love to get your feedback! You can do this in a number of ways.
In your app of choice (e.g. Spotify, Apple Podcasts):
- leave a comment
- leave a rating
- share the podcast with your colleagues and friends
- Contact healthCALHNcommunications@sa.gov.au.
More about the research
About the researcher
Professor Branford is Head of the Leukaemia Unit in the Department of Genetics and Molecular Pathology at SA Pathology and a Section Leader at the Centre for Cancer Biology, University of South Australia.
Her research focusses on understanding the mechanisms of drug resistance and she leads the International CML Genomics Alliance. The Alliance aims to establish a genomically-based risk classification system to enhance patient management.
She received the 2021 Rowley Prize from the International CML Foundation for significant contribution to the understanding of the biology of chronic myeloid leukaemia.